The multi-herbal drug STW 5 (Iberogast®) has prosecretory action in the human intestine

Neurogastroenterology and Motility

Volumn 21, Issue 11, 2009, Pages

  Krueger, D ^a   Gruber, L ^a   Buhner, S ^a   Zeller, F ^b   Langer, R ^a   Seidl, S ^a   Michel, K ^a   Schemann, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b Department of Surgery   (Germany)

Author keywords

Chloride secretion; Cystic fibrosis transmembrane conductance regulator; Enteric nervous system; Human intestine; Iberogast

Indexed keywords

4 ACETAMIDO 4 ISOTHIOCYANATOSTILBENE 2,2 DISULPHONIC ACID; AMILORIDE; BUMETANIDE; CALCIUM CHANNEL BLOCKING AGENT; GLIBENCLAMIDE; HERBACEOUS AGENT; IBEROGAST; MDL 12330; N (2 PHENYLCYCLOPENTYL)AZACYCLOTRIDECAN 2 IMINE; TETRODOTOXIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

AGED; ARTICLE; BLEEDING; CELL LINE; COLON POLYP; CONSTIPATION; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DYSPEPSIA; ENTEROPATHY; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; ILEUS; INTESTINE DIVERTICULOSIS; INTESTINE INNERVATION; INTESTINE MUCOSA; INTESTINE SECRETION; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MEMBRANE CONDUCTANCE; NEUROIMAGING; PRIORITY JOURNAL; SIGMOID; SPIKE; STOMACH CARCINOMA; SUBMUCOSA;

AGED; AGED, 80 AND OVER; CELL LINE; EPITHELIAL CELLS; FEMALE; HUMANS; INTESTINAL MUCOSA; ION CHANNEL GATING; MALE; MIDDLE AGED; NEURONS; PLANT EXTRACTS;

EID: 70349682327     PISSN: 13501925     EISSN: 13652982     Source Type: Journal    
DOI: 10.1111/j.1365-2982.2008.01242.x     Document Type: Article

References (30)

1. Wegener T, Wagner H. The active components and the pharmacological multi-target principle of STW 5 (Iberogast). Phytomedicine 2006 13 (Suppl. 5 20 35.
2. Melzer J, Rösch W, Reichling J, Brignoli R, Saller R. Meta-analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004 20 : 1279 1287.
3. von Arnim U, Peitz U, Vinson B, Gundermann KJ, Malfertheiner P. STW 5, a phytopharmacon for patients with functional dyspepsia: results of a multicenter, placebo-controlled double-blind study. Am J Gastroenterol 2007 102 : 1268 1275.
4. Hohenester B, Rühl A, Kelber O, Schemann M. The herbal preparation STW 5 (lberogast) has potent and region-specific effects on gastric motility. Neurogastroenterol Motil 2004 16 : 765 773.
5. Schemann M, Michel K, Zeller F, Hohenester B, Rühl A. Region-specific effects of STW 5 (Iberogast) and its components in gastric fundus, corpus and antrum. Phytomedicine 2006 13 (Suppl. 5 90 9.
6. Pilichiewicz AN, Horowitz M, Russo A et al. Effects of Iberogast on proximal gastric volume, antropyloroduodenal motility and gastric emptying in healthy men. Am J Gastroenterol 2007 102 : 1276 1283.
7. Schempp H, Weiser D, Kelber O, Elstner EF. Radical scavenging and anti-inflammatory properties of STW 5 (Iberogast) and its components. Phytomedicine 2006 13 (Suppl. 5 36 44. (Pubitemid 44809859)
8. Khayyal MT, Seif-El-Nasr M, El-Ghazaly MA, Okpanyi SN, Kelber O, Weiser D. Mechanisms involved in the gastro-protective effect of STW 5 (Iberogast) and its components against ulcers and rebound acidity. Phytomedicine 2006 13 (Suppl. 5 56 66.
9. Germann I, Hagelauer D, Kelber O et al. Antioxidative properties of the gastrointestinal phytopharmaceutical remedy STW 5 (Iberogast). Phytomedicine 2006 13 (Suppl. 5 45 50.
10. Kelber O, Wittwer A, Lapke C et al. Ex vivo/in vitro absorption of STW 5 (Iberogast) and its extract components. Phytomedicine 2006 13 (Suppl. 5 107 113.
11. Wagner H. Multitarget therapy - the future of treatment for more than just functional dyspepsia. Phytomedicine 2006 13 (Suppl. 5 122 129.
12. Madisch A, Holtmann G, Plein K, Hotz J. Treatment of irritable bowel syndrome with herbal preparations: results of a double-blind, randomized, placebo-controlled, multi-centre trial. Aliment Pharmacol Ther 2004 19 : 271 279.
13. Liu JP, Yang M, Liu YX, Wei ML, Grimsgaard S. Herbal medicines for treatment of irritable bowel syndrome. Cochrane Database Syst Rev 2006 1 : CD004116.
14. Ammon HP, Kelber O, Okpanyi SN. Spasmolytic and tonic effect of Iberogast (STW 5) in intestinal smooth muscle. Phytomedicine 2006 13 (Suppl. 5 67 74. (Pubitemid 44809870)
15. Larsson MH, Simrén M, Thomas EA, Bornstein JC, Lindström E, Sjövall H. Elevated motility-related transmucosal potential difference in the upper small intestine in the irritable bowel syndrome. Neurogastroenterol Motil 2008 19 : 812 820.
16. Andresen V, Camilleri M, Busciglio IA et al. Effect of 5 days linaclotide on transit and bowel function in females with constipation-predominant irritable bowel syndrome. Gastroenterology 2007 133 : 761 768.
17. Johanson JF, Drossman DA, Panas R, Wahle A, Ueno R. Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation. Aliment Pharmacol Ther 2008 27 : 685 696.
18. Harris LA, Crowell MD. Linaclotide, a new direction in the treatment of irritable bowel syndrome and chronic constipation. Curr Opin Mol Ther 2007 9 : 403 410.
19. Lacy BE, Levy LC. Lubiprostone: a novel treatment for chronic constipation. Clin Interv Aging 2008 3 : 357 364.
20. Schicho R, Krueger D, Zeller F et al. Hydrogen sulfide is a novel prosecretory neuromodulator in the Guinea-pig and human colon. Gastroenterology 2006 131 : 1542 1552.
21. Breunig E, Michel K, Zeller F, Seidl S, Weyhern CW, Schemann M. Histamine excites neurones in the human submucous plexus through activation of H1, H2, H3 and H4 receptors. J Physiol 2007 583 : 731 742.
22. Neunlist M, Peters S, Schemann M. Multisite optical recording of excitability in the enteric nervous system. Neurogastroenterol Motil 1999 11 : 393 402.
23. Thiagarajah JR, Broadbent T, Hsieh E, Verkman AS. Prevention of toxin-induced intestinal ion and fluid secretion by a small-molecule CFTR inhibitor. Gastroenterology 2004 126 : 511 519.
24. Xue J, Askwith C, Javed NH, Cooke HJ. Autonomic nervous system and secretion across the intestinal mucosal surface. Auton Neurosci 2007 133 : 55 63.
25. Schultheiss G, Siefjediers A, Diener M. Muscarinic receptor stimulation activates a Ca(2+)-dependent Cl(-) conductance in rat distal colon. J Membr Biol 2005 204 : 117 127.
26. Liu CY, Müller MH, Glatzle J et al. The herbal preparation STW 5 (Iberogast) desensitizes intestinal afferents in the rat small intestine. Neurogastroenterol Motil 2004 16 : 759 764.
27. Sibaev A, Yuece B, Kelber O et al. STW 5 (Iberogast) and its individual herbal components modulate intestinal electrophysiology of mice. Phytomedicine 2006 13 (Suppl. 5 80 9.
28. Abdel-Aziz H, Wadie W, Khayyal MT, Kelber O, Okpanyi S, Weiser D. Pharmacological evidence for the anti-inflammatory effect of STW 5 in colonic inflammation in vivo. Planta Med 2007 72 : 992 (abstract).
29. Abdel-Aziz H, Wadie W, Kelber O, Vinson B, Weiser D, Khayyal MT. Anti-inflammatory effect of STW 5 in colonic inflammation in vivo. Gut 2007 56 : A154.
30. Schemann M, Krueger D, Gruber L et al. Action profile of the phytomedicine STW 5 suggests novel indications. Neurogastroenterol Motil 2008 20 (Suppl. 1 95.